Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | TUBB4A | P04350 | 6/20 | 0.43 |
| ▸ | TUBB | P07437 | 6/20 | 0.43 |
| ▸ | TUBA3C | P0DPH7 | 6/20 | 0.43 |
| ▸ | TUBA1B | P68363 | 6/20 | 0.43 |
| ▸ | TUBA4A | P68366 | 6/20 | 0.43 |
| ▸ | TUBB4B | P68371 | 6/20 | 0.43 |
| ▸ | TUBB3 | Q13509 | 6/20 | 0.43 |
| ▸ | TUBB2A | Q13885 | 6/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7242800 | 0.79 | ALDH1A1 (0.54) | KDM4EALDH1A1HPGDMAPTNPC1 | |
| SCHEMBL19331422 | 0.75 | NPC1 (0.49) | KDM4EALDH1A1HPGDMAPTNPC1 | |
| SCHEMBL1494400 | 0.74 | KDM4E (0.57) | KDM4EALDH1A1HPGDMAPTNPC1 | |
| SCHEMBL9434782 | 0.73 | KDM4E (0.50) | KDM4EALDH1A1HPGDMAPTNPC1 | |
| SCHEMBL3013701 | 0.72 | ALDH1A1 (0.62) | KDM4EALDH1A1HPGDMAPTNPC1 | |
| SCHEMBL12255347 | 0.72 | AKR1C2 (0.50) | KDM4EALDH1A1MAPTMTNR1AMTNR1B | |
| SCHEMBL12255227 | 0.72 | AKR1C2 (0.38) | ALDH1A1MAPTMTNR1AMTNR1BGAA | |
| SCHEMBL5803546 | 0.72 | KDM4E (0.54) | KDM4EALDH1A1HPGDMAPTNPC1 | |
| SCHEMBL23000249 | 0.70 | MAPT (0.49) | KDM4EALDH1A1HPGDMAPTNPC1 | |
| SCHEMBL8794978 | 0.70 | KDM4E (0.62) | KDM4EALDH1A1HPGDMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066309-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2025-02-27 | — | — | US | disclosed |
| US-20250025462-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | ROCHE PALO ALTO LLC (US) | 2025-01-23 | — | — | US | disclosed |
| US-20240158356-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2024-05-16 | — | — | US | disclosed |
| US-20230100975-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2023-03-30 | — | — | US | disclosed |
| US-20210008071-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | ROCHE PALO ALTO LLC (US) | 2021-01-14 | — | — | US | disclosed |
| US-20210009531-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2021-01-14 | — | — | US | disclosed |
| US-20200115347-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2020-04-16 | — | — | US | disclosed |
| US-20190270713-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2019-09-05 | — | — | US | disclosed |
| US-20190016688-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2019-01-17 | — | — | US | disclosed |
| US-20180311240-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | ROCHE PALO ALTO LLC (US) | 2018-11-01 | — | — | US | disclosed |
| US-8524725-B2 | Methods of using diaminopyrimidine as P2X3 and P2X⅔ receptor modulators for treatment of respiratory and gastrointestinal diseases | ROCHE PALO ALTO LLC (US) | 2013-09-03 | — | — | US | disclosed |
| US-20130225570-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | ROCHE PALO ALTO LLC (US) | 2013-08-29 | — | — | US | disclosed |
| EP-1725540-B1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-09-12 | — | — | EP | disclosed |
| US-20120122859-A1 | METHODS OF USING DIAMINOPYRIMIDINE AS P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | ROCHE PALO ALTO LLC. | 2012-05-17 | — | — | US | disclosed |
| US-8008313-B2 | Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases | ROCHE PALO ALTO LLC (US) | 2011-08-30 | — | — | US | disclosed |
| EP-2343282-A1 | Diaminopyrimidines as P2X3 and P2X2/3 antagonists | F. Hoffmann-La Roche AG (CH) | 2011-07-13 | — | — | EP | disclosed |
| US-20110077242-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC | 2011-03-31 | — | — | US | disclosed |
| US-7858632-B2 | Purinergic receptor antagonists; genitourinary and pain-related diseases; for example, 5-(2-isopropyl-4,5-dimethoxybenzyl)-pyrimidine-2,4-diamine | ROCHE PALO ALTO LLC (US) | 2010-12-28 | — | — | US | disclosed |
| US-20070049609-A1 | Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20050209260-A1 | Purinergic receptor antagonists; genitourinary and pain-related diseases; for example, 5-(2-isopropyl-4,5-dimethoxybenzyl)-pyrimidine-2,4-diamine | ROCHE PALO ALTO LLC | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009531-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | KDM4E 3345/4885ALDH1A1 2017/4885HPGD 814/4885 |
| US-20210008071-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | P2RX3, P2RX2, P2RX1 | KDM4E 3901/4885ALDH1A1 2230/4885HPGD 800/4885 |
| US-20250066309-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | KDM4E 3345/4885ALDH1A1 2017/4885HPGD 814/4885 |
| US-20050209260-A1 | Purinergic receptor antagonists; genitourinary and pain-related diseases; for example, 5-(2-isopropyl-4,5-dimethoxybenzyl)-pyrimidine-2,4-diamine | P2RX3, P2RX2, P2RX1 | KDM4E 2921/4885ALDH1A1 2010/4885HPGD 705/4885 |
| US-20230100975-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | KDM4E 3345/4885ALDH1A1 2017/4885HPGD 814/4885 |
| US-20250025462-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | P2RX3, P2RX2, P2RX1 | KDM4E 3901/4885ALDH1A1 2230/4885HPGD 800/4885 |
| US-20180311240-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | P2RX3, P2RX2, P2RX1 | KDM4E 3901/4885ALDH1A1 2230/4885HPGD 800/4885 |
| US-20240158356-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | KDM4E 3345/4885ALDH1A1 2017/4885HPGD 814/4885 |
| US-20070049609-A1 | Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases | P2RX3, P2RX2, P2RX1 | KDM4E 3901/4885ALDH1A1 2230/4885HPGD 800/4885 |
| US-20190016688-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | KDM4E 3345/4885ALDH1A1 2017/4885HPGD 814/4885 |
| US-20110077242-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | KDM4E 3565/4885ALDH1A1 2077/4885HPGD 1062/4885 |
| US-20200115347-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | KDM4E 3345/4885ALDH1A1 2017/4885HPGD 814/4885 |
| US-20190270713-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | KDM4E 3372/4885ALDH1A1 1982/4885HPGD 768/4885 |
| US-20120122859-A1 | METHODS OF USING DIAMINOPYRIMIDINE AS P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | P2RX3, P2RX2, P2RX6 | KDM4E 3968/4885ALDH1A1 2007/4885HPGD 783/4885 |
| US-20130225570-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | P2RX3, P2RX2, P2RX1 | KDM4E 3901/4885ALDH1A1 2230/4885HPGD 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.